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Purpose: We present a retrospective review of a single tertiary hospital experience in renal artery stent revascularization
with distal protection in patients with ischemic nephropathy. The objectives of the study included preliminary assessment
of the effect of distal protection on procedure-related acute deterioration in renal function and on renal salvage.
Material and methods: All patients had significant atherosclerotic main renal artery stenosis, documented at preprocedural
imaging, and a degree of chronic renal impairment before revascularization. Forty-six renal arteries were treated in 37
patients with preprocedural renal impairment, which was mild in 10 patients, moderate in 19 patients, and severe in 8
patients. Median patient age was 72 years (range, 59-85 years). All patients underwent primary stenting of renal artery
ostial stenoses with adjuvant use of a filter device (Angioguard guide wire system; Cordis Corp, Division of Johnson &
Johnson, Miami, Fla) in the distal main renal artery. The filter baskets were recaptured for pathologic analysis.
Results: Overall, in 95% of patients, including all patients with preprocedural mild or moderate renal impairment, renal
function was stabilized or improved after revascularization. In 5% of patients decline in renal function was unchanged. No
patients had acute postprocedural deterioration. Mean follow-up was 12.5 months (range, 2-28 months). These results
are better than in most reports in the literature and also better than in a historical group of similar patients with ischemic
nephropathy who underwent stent revascularization without distal protection at the same institution. The improved
results are thought to be due to prevention of cholesterol atheroembolization during the procedure by the distal filter
baskets. Sixty-five percent of the distal protection baskets contained embolic material, including fresh thrombus, chronic
thrombus, atheromatous fragments, and cholesterol clefts.
Conclusion: A distal protection device may significantly improve results during stent revascularization. There are a number
of unique demands on a renal protection device, and the ideal device has not yet been developed. (J Vasc Surg 2003;38:
962-8.)
Atherosclerotic renal artery stenosis is a significant
cause of chronic renal failure,1 particularly in elderly pa-
tients.2 Moreover, at least 50% of significant renal artery
stenoses will progress.3,4 The results of renal artery angio-
plasty in patients with ischemic nephropathy have been
mixed, but generally disappointing.5 We postulated that
procedure-related atheroembolization contributes to the
unfavorable outcome with this procedure. Early experience
with renal angioplasty and stenting, with distal protection
of the main renal artery, is reported in a patient group with
ischemic nephropathy.
MATERIAL AND METHODS
Retrospective data were analyzed for consecutive pa-
tients with ischemic nephropathy and atherosclerotic renal
artery stenosis. The diagnosis of ischemic nephropathy was
made on the basis of chronic renal impairment and demon-
strable significant main renal artery stenosis. No patients
had significant proteinuria, which would suggest other
causes of nephropathy.
Patients were referred by hospital-based specialist refer-
ral services, including renal medicine, cardiology, and vas-
cular surgery. All patients had demonstrated a decline in
renal function over the previous 6 to 12 months. Patients
with hypertension (65%) were referred for possible im-
provement in control of blood pressure and maintenance of
renal function; the remainder were referred for preservation
of renal function (renal salvage). No patients were primarily
referred for treatment of cardiac complications such as flash
pulmonary edema.
Forty-six renal arteries in 37 patients with ischemic
nephropathy underwent renal artery angioplasty and stent-
ing, with distal main renal artery protection, at Auckland
Hospital between June 2000 and October 2002 (28
months). The patient group included 27 men (73%) and 10
women (27%), with median age 72 years (range, 59-85
years). Serum creatinine concentration (SCr) measured
immediately before renal artery revascularization was used
to indirectly calculate creatinine clearance with the
Cockcroft-Gault equation. On the basis of this indirect
creatinine clearance calculation, patients were divided into
three groups, that is, with mild, moderate, or severe renal
impairment. Ten patients had mild renal impairment (cre-
atinine clearance, 40 mL/min), 19 patients had moder-
ate renal impairment (creatinine clearance 15-40 mL/
min), and 8 patients had severe renal impairment
(creatinine clearance 15 mL/min). The preintervention
diagnosis of renal artery stenosis was made with magnetic
From the Departments of Radiologya and Vascular Surgery,b Auckland
Hospital.
Competition of interest: none.
Reprint requests: Dr Andrew Holden, Department of Radiology, Auckland
Hospital, Park Road, Auckland, New Zealand. (e-mail: andrewh@adhb.
govt.nz).
Copyright © 2003 by The Society for Vascular Surgery.
0741-5214/2003/$30.00  0
doi:10.1016/S0741-5214(03)00606-2
962
resonance angiography in 26 patients (70%), digital sub-
traction angiography in 10 patients (27%), and renovascu-
lar Doppler scanning in 1 patient (3%). All stenoses in-
volved the main renal artery ostium, defined as stenosis
without a non-diseased renal arterial segment between the
lesion and the aortic lumen. In 9 patients bilateral high-
grade renal artery stenosis was treated during a single
procedure; in the remaining 28 patients single renal arteries
were treated. Of these, 12 patients had complete occlusion
of the contralateral main renal artery, and 2 patients had
previously undergone nephrectomy. In 4 patients the con-
tralateral main renal artery was of normal caliber, but ab-
normal renal function and hypertension were present. In
the remaining 10 patients contralateral renal artery stenosis
was not treated, because of small kidney (7 cm) on
ultrasound scans or magnetic resonance images (n  6) or
a diffusely small-caliber main renal artery (n  4).
Treated main renal artery stenosis was assessed as
greater than 80% diameter loss compared with the closest
downstream arterial segment (beyond any poststenotic di-
latation) at preprocedural digital subtraction angiography
or contrast enhanced magnetic resonance angiography in
36 patients. The severity of stenosis was confirmed at the
interventional procedure, although intra-arterial pressure
measurements were not routinely obtained. In one patient
a renovascular Doppler scan suggested the presence of
critical stenosis, which was confirmed on the procedural
angiogram.
Patients were admitted to hospital the day before the
procedure for overnight intravenous hydration, which was
continued for approximately 24 hours after the procedure.
In 12 patients (32%) an intra-arterial gadolinium chelate
was used as the procedural contrast medium, up to a dose
limit of 0.3 mmol/kg. The chelates used included gadodia-
mide (Omniscan; Amersham Health, Oslo, Norway) and
gadopenetate (Magnevist; Schering AG, Berlin, Germany),
both in concentrations of 0.5 mmol/mL. In the remaining
patients only iodinated contrast medium was used. In the
last five of these patients oral acetylcysteine was adminis-
tered (600 mg twice daily) the day before and the day of the
procedure. All patients received intra-arterial bolus doses of
heparin (5000 IU) and glyceryl trinitrate (mean, 175 g
per patient) during the procedure.
A common femoral artery approach was used in all
patients. After 0.018-inch guide wire traversal of the steno-
sis, an 8F guide catheter with central dilator was introduced
through the stenosis, effectively producing “Dotter dila-
tion” of the stenosis up to the outer diameter of the 8F
guide catheter (2.7 mm). This enabled safe delivery of the
distal protection device and subsequent primary stenting of
the stenosis (Fig 1). No stenosis required predilatation to
deliver the guide catheter. The distal protection device used
in all patients was the Angioguard emboli capture guide
wire system (Cordis Corp, Division of Johnson & Johnson,
Miami, Fla), deployed in the distal main renal artery. This
device consists of a 0.014-inch guide wire with a polyure-
thane basket at the distal end. The basket has 100-m pores
and is supported by eight nitinol struts. A balloon-expand-
able stent was then primarily deployed after withdrawal of
the guide catheter. Angiography via the guide catheter in
anteroposterior and oblique planes was performed before
Fig 1. Right renal artery angioplasty and stenting with distal renal
artery protection. A, Abdominal aortogram with gadolinium che-
late as intra-arterial contrast medium. Stenosis involving ostium of
right main renal artery is confirmed (arrow). B, Angiogram ob-
tained in left anterior oblique position via guide catheter enables
accurate position of stent relative to renal artery ostium. Filter lies
in distal main renal artery (arrow). C, Completion angiogram
obtained before removal of distal filter.
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stent deployment, to assist in accurate localization of the
renal artery ostium. Most stents (87%) were inflated to a
diameter of 6 mm, with the remainder (13%) inflated to 7
mm. After completion angiography, the distal basket was
recaptured and sent for pathologic analysis.
Renal function alterations after renal artery revascular-
ization were determined with measurement of SCr. In all
patients SCr was measured within 24 hours after the pro-
cedure (day 1 SCr). The most recent SCr measurement was
also recorded (renal follow-up SCr). Creatinine clearance
was again indirectly calculated with the Cockcroft-Gault
equation. Changes in renal function after the procedure
were classified as renal function improved (follow-up SCr
20% below pretreatment SCr), renal function stabilized
(follow-up SCr 20% above or below pretreatment SCr),
or unchanged decline in renal function (follow-up SCr
20% above pretreatment SCr, with decline occurring at a
rate similar to pretreatment decline). Day 1 SCr more than
20% below pretreatment SCr indicated procedure-related
acute deterioration.
Baseline renovascular Doppler scanning was performed
at 6 weeks in 30 patients (81%). These studies included
direct interrogation of the treated main renal artery plus
indirect assessment of the stenosis by obtaining spectral
waveforms from intrarenal segmental arteries, with mea-
surement of acceleration times and resistive indices. In the
patient group with hypertension, review of clinical records
and patient telephone contact was performed to assess
alterations in blood pressure control after renal artery re-
vascularization.
A retrospective analysis of 22 arteries in 20 patients
with ischemic nephropathy was performed. These patients
underwent renal artery stent revascularization without dis-
tal renal artery protection at the same institution in the 2
years before the current study (October 1998-May 2002).
These patients were a little younger (median age, 69 years),
again with a male predominance (60%). Compared with
patients who underwent revascularization with distal renal
artery protection, these 20 patients had better renal func-
tion before revascularization, that is, mild renal impairment
(creatinine clearance40 mL/min) in 25% of patients and
moderate renal impairment (creatinine clearance 15-40
mL/min) in 75% of patients. No patients had severe renal
impairment, and none received intra-arterial gadolinium or
acetylcysteine.
RESULTS
Changes in renal function after stent revascularization
with distal renal artery protection are summarized in the
Table. In 95% of patients renal function was stabilized or
improved. Mean follow-up was 12.5 months (range, 2-28
months). In all patients with mild or moderate renal im-
pairment before revascularization, renal function improved
or was stabilized after the procedure (Figs 2, 3). In the
group with severe renal impairment, 2 patients (5%) had
unchanged decline in renal function (Fig 4). One of these
patients also had longstanding, poorly controlled diabetes
and diabetic nephropathy, and was receiving dialysis ther-
apy 5 months after revascularization. In the remaining
patients in this group renal function improved or was
stabilized after revascularization. In no patient was there
acute decline in renal function after the procedure.
One patient experienced short-term improvement in
renal function after bilateral renal artery stenting with distal
renal artery protection. However, endoluminal repair of an
infrarenal abdominal aortic aneurysm was performed 1
month later with the stented renal arteries unprotected
during the procedure. Severe renal and peripheral athero-
embolization developed immediately after the procedure.
This patient’s aorta was severely atheromatous, which was
likely the source of atheroembolization due to stiff guide
wire irritation during the endoluminal procedure.
The distal protection baskets contained macroscopic or
microscopic contents in 30 of 46 cases (65%). These in-
cluded fresh thrombus, chronic thrombus, atheromatous
fragments, and cholesterol clefts. The remainder of the
baskets were either empty or contained insufficient material
to survive processing.
Changes in renal function after stent revascularization
in the control group without distal renal artery protection
Overall results of renal artery stent revascularization
Outcome
No. of procedures
Without
distal
protection
With distal
protection
n % n %
Improved renal function 0 14 38
Stabilized renal function 15 75 21 57
Unchanged decline 4 20 2 5
Acute deterioration 1 5 0
Fig 2. Changes in creatinine clearance after renal angioplasty and
stenting with distal renal artery protection in patients with mild
chronic renal impairment (creatinine clearance 40 mL/min).
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are summarized in the Table. Although this patient group
had better pretreatment renal function, 25% of patients
experienced either unchanged decline or acute deteriora-
tion in renal function after the procedure.
In the 81% of patients who underwent 6-week post-
treatment renovascular Doppler scanning, all treated renal
arteries (100%) were patent, with no evidence of residual
stenosis. A smaller group of patients (21%) also underwent
6-month renovascular Doppler scanning. In one of these
patients significant in-stent recurrent stenosis was demon-
strated, and was confirmed at angiography. Management
was with redilatation.
Before revascularization, patients with hypertension
were receiving, on average, 2.5 antihypertensive medica-
tions. After renal artery revascularization, hypertension was
not “cured,” but the number of medications was reduced in
14 patients (57%), with the overall average number of
medications reduced to 1.9 per patient. In a further 8
patients (33%), blood pressure was less labile, even though
the number of medications was not changed.
DISCUSSION
Common indications for endovascular revasculariza-
tion in renal artery stenosis are renovascular hypertension
and ischemic nephropathy. Many studies report satisfactory
symptomatic improvement with renal artery revasculariza-
tion in patients with renovascular hypertension.6,7 Meta-
analysis by Palmaz of eight studies, with 349 patients with
renovascular hypertension, demonstrated improved blood
pressure control in 56% of patients with endovascular stent
revascularization, and resolution of hypertension in 10% of
patients.5 However, several randomized prospective trials
have shown little advantage of renal angioplasty over opti-
mum medical management in patients with normal renal
function and blood pressure well-controlled with medica-
tion.8,9 These studies may not represent best endovascular
practice, often including angioplasty alone rather than stent
placement. Primary angioplasty with stenting significantly
improves renal artery patency in ostial atherosclerotic dis-
ease.10-12 Patients with hypertension that is resistant to
medical therapy and with progressive renal insufficiency
respond better to endovascular revascularization.
A number of investigations have enabled more accurate
identification of patients with hypertension who will re-
spond to endovascular treatment. Clinical predictors in-
clude flash pulmonary edema,13-15 hypertension resistant
to medical therapy,16 rapid decline in renal function,16 and
middle age rather than old age.17 Patients with decline in
renal function after commencing angiotensin converting
enzyme (ACE) inhibitor therapy also have a high incidence
of renal artery stenosis.18 The most sensitive noninvasive
investigations are captopril scintigraphy and Doppler scan-
ning of intrarenal resistive index.17,19,20 Selective measure-
ment of renal vein rennin concentration is more invasive
and appears to lack sensitivity as a reliable screening method
for renovascular hypertension.21 Renal vein renin concen-
tration measurement may have a role in identifying patients
with hypertension who will benefit from nephrectomy.22
Ischemic nephropathy is defined as excretory dysfunc-
tion resulting from impaired renal perfusion.23 The role of
renal artery revascularization in ischemic nephropathy is
less clear than in renovascular hypertension. Many retro-
spective studies contain small patient numbers, with brief
follow-up. Meta-analysis by Palmaz of 8 studies, with 349
patients, reported stabilized renal function in 38% of pa-
tients, and unchanged decline in 62% of patients.5 Other
studies report similar or slightly better results.6,24-27 These
studies report a low incidence (15%-25%) of improved renal
Fig 4. Changes in creatinine clearance after renal angioplasty and
stenting with distal renal artery protection in patients with severe
chronic renal impairment (creatinine clearance 15 mL/min).
Fig 3. Changes in creatinine clearance after renal angioplasty and
stenting with distal renal artery protection in patients with moder-
ate chronic renal impairment (creatinine clearance 15-40 mL/
min).
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function after renal artery revascularization. In contrast,
meta-analysis by Leertouwer et al28 of 24 studies described
renal function improvement in 30% of patients after renal
artery angioplasty or stenting. An older meta-analysis re-
viewed studies that assessed surgical renal artery revascular-
ization,29 with reported improved renal function in 55% of
patients. Of interest, one study was excluded from this
meta-analysis because the results were considerably worse
than in the remaining studies. Surgical manipulation of the
atheromatous aorta was associated with a significantly
poorer outcome, presumably due to atheroembolization.
Unlike renovascular hypertension, there are no reliable
predictors of favorable response to revascularization in
ischemic nephropathy. Noninvasive investigations for
hyper-renin states, such as captopril-induced scintigraphy,
do not necessarily predict a favorable response for renal
salvage, especially in patients with normotension. There is
evidence that pre-interventional assessment of intrarenal
resistive indices may have some predictive value.19 There is
no medical alternative that achieves improved renal perfu-
sion in this patient group.
Most studies of endovascular revascularization in isch-
emic nephropathy report procedure-related acute decline
in renal function of 10% to 20%.6,24-27 A possible reason for
this decline is cholesterol atheroembolization. Cholesterol
atheroembolization is embolization of atheromatous
plaque fragments and cholesterol crystals. This is usually
associated with catheter or surgical manipulation of a se-
verely atheromatous aorta.30,31 The condition may present
with acute renal failure, but more commonly with progres-
sive loss of renal function over weeks.31 Cutaneous, gastro-
intestinal, and central nervous system manifestations are
also noted. The reported incidence of cholesterol athero-
embolization as an acute complication of renal artery an-
gioplasty and stenting is low (1%-2%).5 However, the true
incidence is likely much higher, because reported cases are
biopsy-proved and associated with systemic manifestations.
The carotid angioplasty and stenting literature shows that
guide wire and catheter manipulation, and especially angio-
plasty, is associated with distal embolization, as recognized
on transcranial Doppler scans or from clinical symptoms.32
Cerebral protection devices reduce the number of emboli
that reach the target organ (brain) and reduce target organ
damage.33 Endovascular manipulation of the atheroma-
tous renal artery ostium is also a likely source of cholesterol
atheroembolization.
SCr is frequently used as a convenient measure of
functional renal reserve, because creatinine is almost exclu-
sively excreted into the urine by glomerular filtration.
However, SCr is altered by a number of factors, including
muscle mass. Consequently, elderly patients, with reduced
muscle mass, tend to have lower SCr, even if renal function
is impaired. In these patients creatinine clearance is a better
measure of glomerular filtration rate. Because of the large
functional renal reserve, as much as 50% of total glomerular
filtration can be lost before SCr becomes abnormal (Fig 5,
online only).34 However, once the SCr becomes abnormal,
the curve relating GFR to SCr becomes much steeper.
Small reductions in residual functional renal mass are then
associated with exponential elevation in SCr. Thus, if en-
dovascular revascularization is performed in a patient with
renal impairment and is complicated by cholesterol athero-
embolization, a dramatic post-procedural elevation in SCr
is seen. This serious complication has stimulated interest in
use of renal artery protection during endovascular revascu-
larization in patients with ischemic nephropathy.
This study reports initial experience of renal artery stent
revascularization with distal renal artery protection in pa-
tients with ischemic nephropathy. In most patients (95%)
renal function was stabilized or improved. These results are
considerably better than most reported in the literature.
They are also better than for a historical group of renal
revascularization procedures performed at the same institu-
tion but without renal artery protection, even though that
group had better baseline renal function. It is likely that use
of distal renal artery protection contributed to these results.
The pathologic yield from the distal baskets supports this
conclusion (Fig 6). In an unfortunate, but instructive, case,
the patient successfully underwent stent revascularization
of both renal arteries with distal renal artery protection, but
cholesterol atheroembolization subsequently developed
during endoluminal aneurysm repair without protected
renal arteries.
In this study the best results were achieved in patients
with moderate renal impairment (creatinine clearance
15-40 mL/min) before revascularization. These patients
have significant arterial insufficiency, but with a reasonable
amount of functional renal parenchyma, and therefore are
an attractive treatment group.
There is little literature describing use of distal renal
artery protection in revascularization, although safety and
Fig 6. Completion angiogram after stenting of right main renal
artery. Artery is patent to distal filter, but not beyond it, because of
macroscopic emboli within filter. Flow was restored after filter
recapture.
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feasibility with a temporary occlusive balloon has been
demonstrated.35 Our study confirms safety with an alterna-
tive distal protection device, a distal filter. The technical
demands on a renal protection device are different from
those on a cerebral protection device. Cerebral devices that
occlude the relevant artery rely on the excellent collateral
circulation of the circle of Willis to maintain end organ
perfusion. These are not appropriate in renal arteries, which
lack adequate collateral circulation. Experience from the
surgical literature confirms that suprarenal aortic cross-
clamping, even for short periods, is associated with deteri-
oration in renal function in a significant number of pa-
tients.36 A distal filter device that maintains perfusion
throughout the procedure is ideal for renal protection.
Anatomic differences between carotid and renal arteries
place different demands on the stent-protection system. In
carotid bifurcation disease, the access artery (common ca-
rotid artery) and target artery (internal carotid artery) are
essentially parallel. In addition, the external carotid artery
may be used as a guide wire anchor vessel to achieve stable
access. For renal artery ostial disease, the access artery
(abdominal aorta) and target artery are essentially perpen-
dicular, and there is no guide wire anchor vessel. This renal
anatomy places extra demand on the profile of the protec-
tion device and strength of the guide wire to support
angioplasty balloons and stents as they traverse angulated
vessels. Before beginning this study, primary passage of
distal filter systems through renal artery ostial stenoses was
attempted in a number of patients. Guide wire passage was
unsuccessful in most, because of the profile of the distal
filter system, and poor torque control and relative fragility
of the leading guide wire. For these reasons, we decided to
perform Dotter dilation of the stenosis, with a guide cath-
eter and central dilator, up to the outer diameter of the 8F
catheter (2.7 mm). This procedure enables rapid and accu-
rate deployment of the distal filter and placement of the
stent. Although Dotter dilation itself may produce distal
embolization, the absence of any deterioration in creatinine
clearance on day 1 post-procedural measurements suggests
that distal embolization is minimal. The guide catheter
often briefly occludes the renal artery at the level of the
stenosis (Fig 7, online only). This occlusion may prevent
propagation of embolic material into peripheral arterial
branches until the guide catheter is withdrawn. At this
stage, the distal filter is in place. Angioplasty with stenting is
thought to be the most embologenic procedure,32 and the
kidney is also protected at this stage. As the profile of distal
protection devices decrease, primary passage of the protec-
tion device through the renal artery ostium is likely to
become routine.
A number of adjuvant techniques are used to preserve
renal function during endovascular treatment of renal ar-
tery stenosis in ischemic nephropathy. Adequate periproce-
dural hydration appears most important. There is evidence
that acetylcysteine may also be nephroprotective.37 Intra-
arterial gadolinium chelates appear to be less nephrotoxic
than iodinated contrast medium,38 at least at the dosage
used.39 Although they are less radiopaque than iodinated
contrast medium,40 gadolinium chelates can be used to
significantly reduce iodinated contrast requirements. The
effect of intra-arterial gadolinium and acetylcysteine cannot
be accurately assessed in this study, because of the small
number of patients and lack of control subjects.
The ideal renal stent-protection system is not yet avail-
able. Future developments include reduction in protection
device profile, modifications of the angioplasty balloon-
stent design, and use of short guide wires and rapid ex-
change systems. Use of buddy wires may also improve
support during the procedure. The total length of the renal
stent-protection system should be 35 mm or less if most
main renal arteries are to be adequately protected. Use of
magnetic resonance imaging–compatible stents41 would
enable magnetic resonance surveillance after stent revascu-
larization.
CONCLUSIONS
Use of a distal filter device during stent revasculariza-
tion of renal artery stenosis can significantly improve results
in ischemic nephropathy, with either improved or stabilized
renal function in most patients. The filter device prevents
the acute procedure-related decline in renal function that is
seen in 10% to 20% of patients, which appears to be due to
cholesterol atheroembolization. There are specific de-
mands on a protection device in renal arteries, and the ideal
device has not yet been developed.
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